Replies to post #130870 on Biotech Values

[DewDiligence]

I think it's very likely just a generic company "getting in line" to be first for exclusivity when the patent finally expires.

Since Hatch-Waxman was modified in 2003, this ploy does not work unless it induces a favorable settlement with the branded-drug company (BMY in this instance).